			<del>, , , , , , , , , , , , , , , , , , , </del>		ATTORNEY DOCKET		APPLICATION NO		
					ATTORNET DOCKET		APPLICATION NO	•	
INFORMATION DISCLOSURE STATEMENT (37 C.F.R. 1.56, 1.97, and 1.98)									
' P E 37 C.1 .11. 1.50, 1.57, and 1.90)					23164-1	001	08/853,870		
					APPLICANT(S)		00,000,070		
FEB 0 1 1999 (2)					·				
LER O 1 1999					Michael G. Tovey				
SHEET 1 OF 1					FILING DATE		GROUP		
TRADEMARI					May 9, 1	997	1614		
U.S. PATENT DOCUMENTS									
† EX'R	*						U.S. CLASS/	FILING DATE	
INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)		NAME		SUBCLASS	(If appropriate)	
			FOR	FICAL DATE	UT DOCUMENTS		<u>L</u>	L	
FOREIGN PATENT DOCUMENTS									
† EX'R INITIAL	REF.#							TRANSLATION (YES/NO)	
						<del></del>		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
F 1						<u> </u>			
OTHER DOCUMENTS									
† EX'R *									
INIZIAL	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)							
	W	Kaido, T.J., "Interanasal administration of IFN-α/β inhibits the development of visceral tumor metastases,"							
(0)	Journal of Interferon and Cytokine Research, 17:31-36 (1997).								
$\sim$	Х								
- (X)		arthritis in rats," Experimental and Molecular Pathology, 62:123-130 (1995).							
<del>- ∨ √   -</del>									
•.							·		
•									
,					· · · ·				
EXAMINER'S SIGNATURE DATE CONSIDERED									
		`\/\/\/	1	امال	225)				
	/ IV.	VV	/		~ ~   0	2001			
† EXAMINER: / Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in									
conformance and not considered. Include copy of this form in next communication to applicant.									